News

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...
Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...
The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...
UnitedHealthcare says it’s dropping some of its Medicare Advantage plans that collectively cover 600,000 people.
Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...
GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...
The "no cost" surgical benefit signifies the State Health Plan will cover the surgical cost for members that they normally ...
The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...
Trump administration eyes Medicare and Medicaid coverage for weight loss drugs like Wegovy and Ozempic in a five-year pilot ...
The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...
A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...
Washington Post National Health Reporter Paige Winfield Cunningham discusses how the Trump administration is considering ...